Guangzhou Hanfang Pharmaceutical Launches USPGrade Injectable Soybean Oil Quotations

The program supports global pharmaceutical buyers with transparent, internationally certified supply terms for critical injectable excipients.

Guangzhou, China – October 2026 – Guangzhou Hanfang Pharmaceutical Company Limited, a leading provider of high-end pharmaceutical lipid excipients and specialty active pharmaceutical ingredients, today announced the official launch of transparent, customized supply quotations for its USP-grade injectable soybean oil product line for global pharmaceutical manufacturers. The product is designed to address persistent supply chain volatility for high-purity injectable excipients, with core advantages including full traceability from raw material sourcing to finished product release, compliance with global pharmacopeia standards, and stable domestic production capacity free from cross-border supply disruptions. Through this quotation program, the company aims to reduce procurement barriers for biopharmaceutical firms across North America, Europe, Southeast Asia and Latin America, expanding its global footprint in the high-value injectable excipient market. The quotation program is open for immediate submissions, with production and global shipping aligned with existing lead time frameworks for qualified clients.

Core Product and Supply Advantages

High-purity injectable soybean oil produced at the company’s dedicated Guangzhou manufacturing facility meets strict pharmacopeia requirements for energy supplementation and pharmaceutical excipient use, serving as a core raw material for high-end injectable formulations including intravenous nutrition emulsions.

The company’s production process leverages integrated green extraction technology, replacing traditional high-pollution manufacturing workflows to deliver consistent batch quality while reducing environmental impact across the supply chain.

As a domestically developed alternative to imported injectable soybean oil, the product eliminates long lead times and supply chain risks associated with cross-border logistics, supporting more resilient procurement planning for global pharmaceutical manufacturers.

Global Compliance Framework

To meet global market access requirements, the company’s injectable soybean oil product line is supported by a comprehensive portfolio of international regulatory approvals, including EU CEP certification, US FDA US-DMF registration, Mexico Cofepris approval, and India DCGI recognition. These certifications allow the product to meet regulatory requirements across major pharmaceutical markets, with existing distribution networks covering more than 20 countries and regions worldwide.

Quotation Process and Client Support

Global clients can request customized quotations for injectable soybean oil through the company’s official website, with dedicated technical teams providing detailed documentation on product specifications, batch traceability, and lead time estimates. In addition to standard product offerings, the company provides tailored support for clients with specialized formulation requirements, including custom packaging specifications and targeted technical guidance for injectable emulsion development.

Leadership Perspective

The launch of transparent, accessible supply quotations for our injectable soybean oil line reflects our longstanding commitment to building reliable, globally accessible supply chains for critical pharmaceutical excipients, said Xu Wendong, General Manager of Guangzhou Hanfang Pharmaceutical Company Limited. As a national-level specialized and sophisticated enterprise focused on high-end pharmaceutical lipid research, we are positioned to support global biopharmaceutical firms with consistent, certified product supply that meets the highest quality standards.

Industry Context

Global demand for domestically sourced, internationally certified injectable excipients has grown steadily as biopharmaceutical firms seek to reduce supply chain concentration risks across critical raw material categories. Guangzhou Hanfang Pharmaceutical has built its market position by breaking long-standing international monopolies in high-end pharmaceutical lipid excipients, raising domestic production capacity for key injectable materials from 10% to 90% of total domestic demand in recent years.

Forward-Looking Strategy

Moving forward, the company will continue to invest in research and development for high-end pharmaceutical excipients, expanding its global service network to provide localized technical support for clients across key markets. The company will also continue to align its product development roadmap with global pharmacopeia updates, ensuring long-term regulatory compliance for its full portfolio of injectable excipient products.

Company Overview

Guangzhou Hanfang Pharmaceutical Company Limited was established in 1998, as a core state-owned pharmaceutical enterprise under the GPHL group, focused on the research, development, and production of high-end pharmaceutical lipid excipients, specialty active pharmaceutical ingredients, and science-backed health products. The company operates a dedicated production base in Guangzhou, with research and development centers in Guangzhou and Zhuhai Hengqin, serving more than 1000 clients across the globe including leading multinational pharmaceutical firms. The company holds more than 240 patents, and has been recognized with national-level honors including the National May Day Labor Award, National Green Factory designation, and national-level specialized and sophisticated little giant enterprise status. Its core mission is to advance technological self-reliance in the biopharmaceutical sector, delivering safe, reliable, internationally certified products to support global health outcomes. More information is available at http://byshanhanfang.com/.

FAQ

Q: What documentation is provided to support client product registration for injectable soybean oil?
A: The company provides full regulatory documentation including CEP certificates, FDA DMF filings, and pharmacopeia compliance reports to support client registration processes across global markets.

Q: What is the typical lead time for injectable soybean oil orders?
A: Lead times are tailored to client order volumes and destination market requirements, with dedicated account managers providing detailed timeline estimates during the quotation process.

Contact Us

Official Website: https://byshanhanfang.com/
Production Base Address: No. 8 Wenquan Avenue, Wenquan Town, Conghua District, Guangzhou, Guangdong, China
Head Office Address: No. 134 Jiangnan Avenue Middle, Haizhu District, Guangzhou, Guangdong, China